Applied Genetic Technologies Announces Enrollments in Phase 1/2 Clinical Trials

Applied Genetic Technologies (NASDAQ:AGTC) has announced it has reached two milestones in two of its Phase 1/2 clinical trials. As...

AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study

Applied Genetic Technologies (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment...